英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

wisecrack    音标拼音: [w'ɑɪzkr,æk]
n. 俏皮话

俏皮话

wisecrack
n 1: witty remark [synonym: {wisecrack}, {crack}, {sally}, {quip}]
v 1: make a comment, usually ironic

60 Moby Thesaurus words for "wisecrack":
aphorism, apothegm, be merry with, bon mot, boutade, bright idea,
bright thought, brilliant idea, conceit, crack, crack a joke,
crack wise, epigram, facetiae, flash of wit, fleer at,
flight of wit, fun, gag, gibe, gibe at, happy thought, jape, jest,
joke, josh, kid, kid around, make a funny, make fun, make fun of,
mock, mot, nasty crack, persiflage, play of wit, play on words,
pleasantry, poke fun at, pun, quip, quips and cranks, repartee,
retort, ridicule, riposte, sally, scintillate, scintillation,
scoff at, smart crack, smart saying, snappy comeback, sparkle,
stroke of wit, turn of thought, utter a mot, waggery, witticism,
yak


请选择你想看的字典辞典：
单词字典翻译
wisecrack查看　wisecrack　在百度字典中的解释百度英翻中〔查看〕
wisecrack查看　wisecrack　在Google字典中的解释Google英翻中〔查看〕
wisecrack查看　wisecrack　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab . . .
    On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc ) in combination with pertuzumab for the first-line treatment of
  • Enhertu Approved for Any HER2-Positive Solid Cancer
    On August 5, the agency gave an accelerated approval for trastuzumab deruxtecan —often called T-DXd—to treat anyone with any advanced solid cancer if their tumors produce high levels of the protein HER2, or HER2-positive To receive the drug, a patient must already have received at least one prior treatment
  • FDA approves fam-trastuzumab deruxtecan-nxki for breast cancer
    On January 27, 2025, the FDA approved fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer
  • The HER2-directed antibody-drug conjugate DHES0815A in . . .
    Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan To develop a differentiated HER2 ADC, we chose an antibody that
  • Trastuzumab Deruxtecan: Uses, Dosage, Side Effects, Warnings . . .
    Trastuzumab deruxtecan (Enhertu, T-DXd) is a treatment for breast cancer, advanced stomach cancer, non-small cell lung cancer, and solid tumors Includes side effects, FDA approval, package insert, and more
  • Enhertu - Chemocare
    Enhertu - Fam-Trastuzumab Deruxtecan Injection What is this medication? FAM-TRASTUZUMAB DERUXTECAN (fam-tras TOOZ eu mab DER ux TEE kan) treats some types of cancer It works by blocking a protein that causes cancer cells to grow and multiply This helps to slow or stop the spread of cancer cells
  • About ENHERTU4U | ENHERTU® (fam-trastuzumab deruxtecan-nxki . . .
    HER2-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment for metastatic disease or have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer
  • Preparation and Administration | ENHERTU® (fam-trastuzumab . . .
    Find preparation and administration information for ENHERTU See Prescribing Information, including Boxed WARNINGS
  • FDA Grants Trastuzumab Deruxtecan Approval for Endocrine . . .
    Key Takeaways Trastuzumab deruxtecan is approved for HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer post-endocrine therapy progression The drug showed a 36% reduction in disease progression or death risk versus chemotherapy in the DESTINY-Breast06 trial It offers a median progression-free survival exceeding one year and a response rate over 60%, suggesting a new standard of
  • Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast . . .
    Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer Results A total of 1635 patients were randomly assigned (in a 1:1 ratio) to receive T-DXd (818 patients) or T-DM1 (817 patients)





中文字典-英文字典  2005-2009